Михаль Лотем

Научные публикации

• Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer
• Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
• Interferon-stimulated neutrophils as a predictor of immunotherapy response
• Dupilumab for cancer-associated refractory pruritus
• Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer
• The future of affordable cancer immunotherapy
• Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
• Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions
• Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
• Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
• A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells
• Giant congenital melanocytic naevus with a novel CUX1-BRAF fusion mutation treated with trametinib
• Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
• The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma
• Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
• Machine-learning of complex evolutionary signals improves classification of SNVs
• Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)
• Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
• Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
• Early sample tagging and pooling enables simultaneous SARS-CoV-2 detection and variant sequencing
• TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
• Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
• PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
• Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
• Identification of bacteria-derived HLA-bound peptides in melanoma
• COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma
• KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
• Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells
• Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
• SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
• Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study
• Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
• Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
• Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
• Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
• Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells
• Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40
• Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
• Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
• Neurologic complications of immune checkpoint inhibitors
• Soluble SLAMF6 Receptor Induces Strong CD8⁺ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo
• Predictors of responses to immune checkpoint blockade in advanced melanoma
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
• Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma
• Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
• Adoptive cell therapy: past, present and future
• Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report
• Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40
• Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
• Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
• Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants
• Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic
• Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β
• Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells
• Human T cell crosstalk is induced by tumor membrane transfer
• A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases
• Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells
• Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma
• Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma
• Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity
• The clinical effect of the inhibitor of apopotosis protein livin in melanoma
• Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones
• HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine
• Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response
• The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
• Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells
• Long-term survival of uveal melanoma patients after surgery for liver metastases
• Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin
• Metastatic malignant melanoma involving the parotid lymph node region: a clinicopathologic report of 5 cases
• Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs
• Viral carcinogenesis in skin cancer
• Ultraviolet radiation and cutaneous carcinogenesis
• Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression
• Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients
• Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis
• Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients
• Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
• Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma
• PET and Lymphoscintigraphic Evaluation of Malignant Melanomas. The Hadassah Hospital Experience
• Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures
• Mucosal melanoma of the female genital tract is a multifocal disorder
• Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer
• Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma
• CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity
• Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin
• Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
• Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study
• Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma